Clarity Pharmaceuticals (ASX:CU6) Total Stockholders Equity : A$53.06 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Total Stockholders Equity?

Clarity Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$53.06 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Clarity Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 was A$0.40. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Clarity Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.00.

Clarity Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Clarity Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Total Stockholders Equity Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Total Stockholders Equity

92.24

69.18

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial			101.15	92.24	81.78	69.18	53.06

Clarity Pharmaceuticals (ASX:CU6) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Clarity Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(53.06	-	0)	/	134.005
	=	0.40

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Clarity Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	53.06
	=	0.00

Clarity Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines